Friday, August 14, 2009

Zelrix, A Migraine Patch, Is Moving Forward

Filed under: Medicine , Neurology

Pharmaceutical company NuPathe Inc. out of Conshohocken, PA has just announced positive results from Phase III clinical trial of Zelrix™, a novel transdermal patch in clinical development for the treatment of acute migraines. Zelrix relies on the company's proprietary iontophoretic transdermal technology, called SmartRelief™, to continuously deliver sumatriptan. The big idea behind Zelrix, "a thin, disposable, single-use device in a self-contained system," is to give migraine sufferers a new therapeutic option with a proven medication, so they can stick on a patch and get medication fast and consistently, regardless of nausea, vomiting, or other gastric symptoms associated with migraine.

To learn more about the technology and the product, follow these links:

Press release: NuPathe Reports Positive Phase III Results for Zelrix, a Novel Transdermal Patch For Acute Migraine...

Product page: Zelrix...

Technology page: NuPathe Drug Delivery Platforms...

White paper: NP101: A Novel Formulation of Sumatriptan Succinate Utilizing SmartRelief™ Transdermal Technology (.pdf)

(hat tip: The Medical Quack)

                (1)

Name:


Email Address
(will not be published):


URL:

Remember personal info?
(anonymous comments allowed)

Yes No

Comments:

Verification (needed to reduce spam):

Click the "Post" button only once!